Repligen Corporation

Healthcare · Medical Instruments & Supplies

177.20$ -7.8% vs. previous close Closing price · As of: Oct 1, 2026

Statements

Income Statement

Repligen Corporation (RGEN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 204 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement RGEN
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	25	26	31	32	37	42	45	48	50	52	61	71	69	69	76	87	94	109	143	163	178	187	206	208	201	187	165	159	141	156	153	154	155	168	169	182	189	198	194	204	785
Cost of Revenue	11	12	14	14	20	19	20	21	22	23	27	31	31	34	32	37	40	52	60	62	75	82	82	86	87	91	82	79	105	88	76	85	77	129	78	91	88	104	96	96	384
Gross Profit	13	13	17	19	17	22	25	27	27	29	34	40	38	36	44	51	54	56	83	101	103	104	124	121	114	96	84	80	37	68	77	69	77	39	91	91	101	93	98	108	401
Research & Development	1.9	2.0	1.7	1.9	2.0	3.1	3.3	5.8	3.6	3.1	3.6	5.2	5.4	5.2	4.7	4.3	4.4	6.7	7.6	8.4	9.2	9.1	12	10	10	11	12	9.7	11	10	11	11	9.7	12	13	14	14	12	14	14	55
Selling, General & Administrative	7.1	8.6	9.2	11	15	16	16	17	16	17	19	24	25	28	28	27	29	28	39	44	48	52	54	55	54	53	56	49	55	58	61	65	76	61	71	71	74	86	77	77	313
Total Operating Expenses	9.0	11	11	13	17	19	19	22	19	21	23	29	30	30	32	31	32	34	47	53	58	67	64	58	62	47	70	61	32	68	73	75	85	75	84	77	84	75	80	96	336
Operating Income	3.7	2.9	5.7	5.5	-0.4	3.3	6.0	4.3	7.9	7.9	11	11	8.0	5.9	12	20	22	22	36	48	45	37	60	63	53	49	14	19	4.7	-0.9	3.8	1.5	-7.8	-37	6.6	14	17	19	18	12	65
Interest Expense	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	2.9	3.0	3.0	3.0	3.1	3.1	3.1	3.1	3.2	3.2	0.7	0.7	0.8	0.7	0.9	0.9	0.9	8.0	5.5	5.5	5.6	5.5	5.7	5.8	27	5.9	6.0	17	57
Pre-Tax Income	2.2	1.6	4.1	3.7	-2.0	1.5	4.6	3.4	6.6	6.9	11	9.6	1.7	4.3	11	16	18	15	33	44	41	35	59	60	47	53	19	25	11	-8.8	3.7	5.2	-1.1	-39	7.9	18	17	19	1.8	14	52
Income Tax Expense	1.1	-3.5	1.0	-4.8	-6.7	-11	1.1	0.6	1.8	1.2	2.5	1.5	0.0	0.7	0.9	0.2	3.2	-4.9	3.7	8.1	7.7	5.7	12	9.9	7.1	4.3	3.2	5.1	-5.5	17	0.4	1.9	-0.5	-4.7	2.1	3.3	2.2	5.8	-6.6	9.1	11
Net Income	1.2	5.0	3.1	8.4	4.7	12	3.4	2.7	4.8	5.6	8.1	8.1	1.7	3.6	9.8	16	15	20	29	36	33	29	47	50	40	49	15	20	17	-25	3.3	3.3	-0.7	-34	5.8	15	15	13	8.3	5.0	42
EBITDA	5.8	5.4	7.3	7.2	2.7	11	9.9	8.2	12	12	15	16	14	13	18	26	28	25	45	56	54	49	71	72	60	68	34	41	32	9.5	30	27	21	2.1	36	48	47	45	32	-2.4	122

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings